Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
Gut. 2021 Jun;70(6):1139-1146. doi: 10.1136/gutjnl-2020-321825. Epub 2020 Sep 30.
Germline pathogenic (P) variants cause Li-Fraumeni syndrome (LFS), an aggressive multitumor-predisposing condition. Due to the implementation of multigene panel testing, variants have been detected in individuals without LFS suspicion, for example, patients with colorectal cancer (CRC). We aimed to decipher whether these findings are the result of detecting the background population prevalence or the aetiological basis of CRC.
We analysed in 473 familial/early-onset CRC cases and evaluated the results together with five additional studies performed in patients with CRC (total n=6200). Control population and LFS data were obtained from Genome Aggregation Database (gnomAD V.2.1.1) and the International Agency for Research on Cancer (IARC) database, respectively. All variants were reclassified according to the guidelines of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG/AMP), following the ClinGen Expert Panel specifications.
P or likely pathogenic (LP) variants were identified in 0.05% of controls (n=27/59 095) and 0.26% of patients with CRC (n=16/6200) (p<0.0001) (OR=5.7, 95% CI 2.8 to 10.9), none of whom fulfilled the clinical criteria established for testing. This association was still detected when patients with CRC diagnosed at more advanced ages (>50 and>60 years) were excluded from the analysis to minimise the inclusion of variants caused by clonal haematopoiesis. Loss-of-function and missense variants were strongly associated with CRC as compared with controls (OR=25.44, 95% CI 6.10 to 149.03, for loss of function and splice-site alleles, and OR=3.58, 95% CI 1.46 to 7.98, for missense P or LP variants).
P variants should not be unequivocally associated with LFS. Prospective follow-up of carriers of germline P variants in the absence of LFS phenotypes will define how surveillance and clinical management of these individuals should be performed.
胚系致病性 (P) 变异可导致李-佛美尼综合征 (LFS),这是一种具有侵袭性的多肿瘤易患疾病。由于多基因panel 检测的实施,即使在没有 LFS 可疑的个体中,也发现了变异,例如结直肠癌 (CRC) 患者。我们旨在破译这些发现是源于检测背景人群的患病率还是 CRC 的病因基础。
我们分析了 473 例家族性/早发性 CRC 病例,并将结果与另外五项在 CRC 患者中进行的研究(总计 n=6200)进行了评估。对照人群和 LFS 数据分别来自基因组聚合数据库 (gnomAD V.2.1.1) 和国际癌症研究机构 (IARC) 数据库。所有变异均根据美国医学遗传学与基因组学学院和分子病理学协会 (ACMG/AMP) 的指南进行了重新分类,遵循 ClinGen 专家小组的规范。
在 59095 名对照者(n=27)中发现了 P 或可能致病性 (LP) 变异,在 6200 名 CRC 患者中发现了 0.26%(n=16)(p<0.0001)(OR=5.7,95%CI 2.8 至 10.9),他们均未达到 检测的临床标准。当从分析中排除年龄较大(>50 岁和>60 岁)诊断为 CRC 的患者以尽量减少因克隆性造血引起的变异的纳入时,仍然可以检测到这种关联。与对照组相比,失活和错义变异与 CRC 强烈相关(OR=25.44,95%CI 6.10 至 149.03,用于失活和剪接位点等位基因;OR=3.58,95%CI 1.46 至 7.98,用于错义 P 或 LP 变异)。
不应将 P 变异明确与 LFS 相关联。在没有 LFS 表型的情况下,对胚系 P 变异携带者进行前瞻性随访将确定应如何对这些个体进行监测和临床管理。